Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- The Business Consultant behind The First Black-owned BP
- With Pent Up Demand Expected in 2021, Hilton Introduces Hilton EventReady Hybrid Solutions for Meetings and Events
DULLES, Va., Nov. 12, 2020 /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, has signed a commercial supply agreement with Lantheus Holdings, Inc. (the parent company of Progenics Pharmaceuticals, Inc. (Progenics)) to manufacture and distribute Lantheus' lead investigational prostate cancer imaging agent, PyL™ (18F-DCFPYL).
Following U.S. Food and Drug Administration ("FDA") approval, Lantheus will have a critical need for dependable and scalable manufacturing and distribution partners to support PyL™. Under the commercial supply agreement, SOFIE will roll out PyL™ via its national network, which has manufactured PyL™ for Progenics during the clinical trials. SOFIE's network will help meet the expected commercial demand for PyL™ by leveraging its expertise, experience, and distribution capabilities to achieve widespread availability and market coverage.
SOFIE's CEO, Patrick Phelps stated, "Our relationship with Progenics, and now Lantheus, as well as our network capabilities have been greatly refined over the years we've worked on PyL™. With over 500 doses previously manufactured for Progenics' clinical trials, SOFIE is committed to delivering the doses needed, for widespread use post-FDA approval." SOFIE's Chief Technical Officer, Dr. Melissa Moore, added, "Solidifying our relationship with Lantheus via this commercial agreement is the next step in the evolution of our Radiopharmaceutical Contract Manufacturing Organization. SOFIE believes that PyL™ will be an important next generation prostate cancer diagnostic tool and will offer new opportunities to those suffering from this common form of cancer."
More on virginir.com
Paul Blanchfield, Lantheus Chief Commercial Officer commented, "We are delighted to partner with SOFIE as we work toward FDA approval to bring PyL™ to the U.S. prostate cancer community. Consistent, reliable, and on-time delivery of diagnostic PET imaging agents is critical to meeting our supply demands and we look forward to our continued partnership with SOFIE to help patients gain access to PyL™."
About SOFIE
SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine. For more information, please visit https://sofie.com or contact [email protected]
More on virginir.com
About PyL™ for PET Imaging of Prostate Cancer
PyL™ (also known as 18F-DCFPyL) is a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.
About Prostate Cancer
Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in nine men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that each year approximately 191,930 new cases of prostate cancer will be diagnosed and about 33,330 men will die of the disease. Approximately 3.1 million men in the U.S. currently count themselves among prostate cancer survivors.
SOURCE SOFIE
Related Links
https://sofie.com
Following U.S. Food and Drug Administration ("FDA") approval, Lantheus will have a critical need for dependable and scalable manufacturing and distribution partners to support PyL™. Under the commercial supply agreement, SOFIE will roll out PyL™ via its national network, which has manufactured PyL™ for Progenics during the clinical trials. SOFIE's network will help meet the expected commercial demand for PyL™ by leveraging its expertise, experience, and distribution capabilities to achieve widespread availability and market coverage.
SOFIE's CEO, Patrick Phelps stated, "Our relationship with Progenics, and now Lantheus, as well as our network capabilities have been greatly refined over the years we've worked on PyL™. With over 500 doses previously manufactured for Progenics' clinical trials, SOFIE is committed to delivering the doses needed, for widespread use post-FDA approval." SOFIE's Chief Technical Officer, Dr. Melissa Moore, added, "Solidifying our relationship with Lantheus via this commercial agreement is the next step in the evolution of our Radiopharmaceutical Contract Manufacturing Organization. SOFIE believes that PyL™ will be an important next generation prostate cancer diagnostic tool and will offer new opportunities to those suffering from this common form of cancer."
More on virginir.com
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Dollyhood Records Signs Distribution Deal With Sony!
- Stride, Inc. to Sponsor National Forum on Education Equity on February 3, 2021
- West Coast Recording Artist, Composer and Actor, Blue Ragg$ Releases New Music & Theatrical Video
- Swaggerty's Receives Highest Possible Grade from BRC Food Safety Auditors for 8th Consecutive Year
Paul Blanchfield, Lantheus Chief Commercial Officer commented, "We are delighted to partner with SOFIE as we work toward FDA approval to bring PyL™ to the U.S. prostate cancer community. Consistent, reliable, and on-time delivery of diagnostic PET imaging agents is critical to meeting our supply demands and we look forward to our continued partnership with SOFIE to help patients gain access to PyL™."
About SOFIE
SOFIE's vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine. For more information, please visit https://sofie.com or contact [email protected]
More on virginir.com
- Be an Example, Get the Covid Shot
- First Bank & Trust Company Opens Full-Service Office in Hanover, VA
- Former CEO & Founder of Five Star Custom Foods, Acquired by Cargill, Joins CEO Coaching International
- Thiel College names Terry Eddy to Board of Trustees
- CORRECTING and REPLACING Intact Technology, Inc. Develops an Alternative Solution to SolarWinds Orion
About PyL™ for PET Imaging of Prostate Cancer
PyL™ (also known as 18F-DCFPyL) is a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission tomography (PET) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.
About Prostate Cancer
Prostate cancer is the second most common form of cancer affecting men in the United States: an estimated one in nine men will be diagnosed with prostate cancer in his lifetime. The American Cancer Society estimates that each year approximately 191,930 new cases of prostate cancer will be diagnosed and about 33,330 men will die of the disease. Approximately 3.1 million men in the U.S. currently count themselves among prostate cancer survivors.
SOURCE SOFIE
Related Links
https://sofie.com
Filed Under: Business
0 Comments
Latest on virginir.com
- SHELTER, New Works by Artists Byron Keith Byrd, Stefani Byrd, and Fenix Gallery Collective, January 20–February 24, 2021
- Whereoware Strengthens Digital Strategy and Campaign Services with Strategic Hire of Lynne DeRoché as Vice President Strategic Solutions
- INAP Announces Second Phase of Los Angeles Flagship Data Center Expansion Fueled By Hybrid Infrastructure Demand
- AI.Reverie Awarded $950 Million IDIQ Contract for U.S. Air Force Advanced Battle Management System (ABMS)
- Updated ASI Book Helps Association Executives Improve Organizational Performance Now and Post-COVID
- MBK Senior Living Ranks 7th On Fortune Best Workplaces For Aging Services List
- NII Holdings Provides Update On Dissolution Proceedings And Settlement With AT&T
- Stride Inc. Second Quarter Fiscal 2021 Earnings Conference Call Details
- Fifth Gen Media announces Darlene Pope as Chairman of the Advisory Council
- Phinge To Launch Netverse, a Rewards-Based Alternative to Apple and Google Using Innovative Proprietary Technology and Patented Mobile Devices
- Spivey Hall Children's Choir Looks To 2021 Through The Lens of Langston Hughes Poetry
- New Enterprise Tackles Workforce Diversity Challenges
- Clarabridge CX Analytics launches AWS Contact Center Intelligence solution
- Wohler releases AoIP & Analog options for their iVAM1-1
- March Of Dimes And UnitedHealthcare Collaborate To Improve Maternal Health And Reduce Racial Disparities In Outcomes
- FrontStream Payments Empowers Corporations to Drive Employee Engagement and Effect Positive Change Through Secure Charitable Disbursements With Salesforce.org Philanthropy Cloud
- While Supplies Last: Thermal Transfer Label Sale
- The Business Consultant behind The First Black-owned BP
- Overstock Promo: Thermal Transfer Labels On Sale Now
- More FCPOA Shirts Than Any Company In The World